I confirm that the above details are correct:

Signed: ...... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Ursodeoxyc	holic acid
INITIATION – Alagille syndrome or progressive familial intrahepatic cholestasis  Prerequisites (tick boxes where appropriate)	
or O	Patient has been diagnosed with Alagille syndrome
	Patient has progressive familial intrahepatic cholestasis
INITIATION – Chronic severe drug induced cholestatic liver injury Prerequisites (tick boxes where appropriate)	
and	Patient has chronic severe drug induced cholestatic liver injury
and	Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults
0	Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay
INITIATION – Primary biliary cholangitis Prerequisites (tick boxes where appropriate)	
and	Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy  Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis)
INITIATION – Pregnancy Prerequisites (tick box where appropriate)  O Patient diagnosed with cholestasis of pregnancy	
INITIATION – Haematological transplant Prerequisites (tick boxes where appropriate)	
and	Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation  Treatment for up to 13 weeks
INITIATION – Total parenteral nutrition induced cholestasis Prerequisites (tick boxes where appropriate)	
and	Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN  Liver function has not improved with modifying the TPN composition
INITIATION – prevention of sinusoidal obstruction syndrome Prerequisites (tick box where appropriate)	
O The ii syndr	ndividual has leukaemia/lymphoma and requires prophylaxis for medications/therapies with a high risk of sinusoidal obstruction ome